publication date: Nov. 29, 2016
Urothelial Cancer Phase III Keytruda Study Shows Better OS vs. Chemo for Advanced Urothelial Cancer
Merck announced that the phase III KEYNOTE-045 trial investigating the use of Keytruda (pembrolizumab), the company’s anti-PD-1 therapy, in patients with previously treated advanced urothelial cancer, met the primary endpoint of overall survival.
In this trial, Keytruda was superior compared to investigator choice chemotherapy. Based on a pre-specified interim analysis, an independent Data Monitoring Committee has recommended that the trial be stopped early.
“The results of KEYNOTE-045 represent a major breakthrough and will be welcome news for patients dealing with previously treated advanced urothelial cancer,” said Roger Perlmutter, president, Merck Research Laboratories. “We look forward to sharing the findings from this study with the medical community and with regulatory authorities around the world.”
The safety profile of Keytruda in this trial was consistent with that observed in previously reported studies involving patients with advanced urothelial cancer. Results from KEYNOTE-045 will be presented at an upcoming medical meeting.
The Keytruda clinical development program includes more than 30 tumor types in more than 360 clinical trials, including nearly 200 trials that combine Keytruda with other cancer treatments. For genitourinary cancers, Merck has the largest immuno-oncology clinical development program in bladder cancer, with 27 trials underway involving Keytruda as monotherapy and in combination, including four registration-enabling studies.
KEYNOTE-045 is … Continue reading CCL Nov 2016 – Phase III Keytruda Study Shows Better OS vs. Chemo for Advanced Urothelial Cancer
To access this members-only content, please log in.
If you're not a subscriber why not join today?
If you believe you should be able to view this area but cannot log in, then please contact us
and we will try to rectify this issue as soon as possible.
To gain access to the members only content click here
You will be given immediate access to premium content on the site.Click here to join.